Related to Genentech and Pfizer Join the Antibody-Drug Conjugate Bandwagon

• Pfizer and Takeda Ink Co-Promotion Deal for Late-Stage RA Therapy
  
• Charles River to Distribute Pfizer Research Models
  
• Genentech and Curis' Basal Cell Carcinoma Drug Meets Primary Endpoint in Pivotal Study
  
• Pfizer to Attack Lysosomal Storage Diseases with Zacharon’s Small Molecule Approach
  
• Phase III Failure Leads Medivation and Pfizer to Ditch Dimebon for Huntington Disease
  
• Pfizer’s Neusentis Partners with Cellzome on Stem Cell Epigenetics Research
  
• Pfizer Selects Parexel and Icon to Implement and Manage Clinical Trials
  
• ImmunoGen Gets $2M with Bayer Filing IND for Cancer Drug
  
• Pivotal Study Results Lead Genentech to Project Vismodegib Filing in U.S. During 2011
  
• Synthon Takes Over Syntarga for Antibody-Drug Conjugate Platform
  
• Pfizer Gains Patent from Cell Signaling Technology to Enhance Companion Diagnostic Efforts
  
• Pfizer Establishes Center for Therapeutic Innovation Partnership with UC San Diego
  
• Pfizer Allies with Qiagen to Develop Companion Diagnostic for NSCLC Drug Candidate
  
• Argenta Seals Third Extension to Drug Discovery Services Agreement with Genentech
  
• Seattle Genetics’ Antibody-Drug Conjugate Receives FDA Okay to Treat Lymphomas
  
• Puma Acquires Global Rights to Pfizer’s Phase III Breast Cancer Drug Neratinib
  
• Pfizer Negotiates Global Rights to GlycoMimetics’ Phase II Sickle Cell Crisis Drug
  
• Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate
  
• Pfizer Returns Two Early-Stage Anti-TNF-Alpha Nanobodies to Ablynx
  
• Children's Hospital Boston and Pfizer Join Forces Against Duchenne Muscular Dystrophy